Results 121 to 130 of about 1,869,033 (226)

NAC Pre-Administration Prevents Cardiac Mitochondrial Bioenergetics, Dynamics, Biogenesis, and Redox Alteration in Folic Acid-AKI-Induced Cardio-Renal Syndrome Type 3. [PDF]

Antioxidants (Basel), 2023
Cuevas-López B, Romero-Ramirez EI, García-Arroyo FE, Tapia E, León-Contreras JC, Silva-Palacios A, Roldán FJ, Campos ONM, Hernandez-Esquivel L, Marín-Hernández A, Gonzaga-Sánchez JG, Hernández-Pando R, Pedraza-Chaverri J, Sánchez-Lozada LG, Aparicio-Trejo OE.   +14 more
europepmc   +1 more source

The Binding of Fibroblast Growth Factor 23 (FGF23) to FGF Receptor‐αKlotho Complex Increases Sinoatrial Electrical Activity

Acta Physiologica, Volume 242, Issue 10, October 2026.
ABSTRACT Aim This study aims to investigate whether the Fibroblast Growth Factor 23 (FGF23) modulates the electrical activity of sinoatrial (SAN) cells. The canonical function of FGF23 is to regulate body phosphorus and calcium homeostasis by activating the FGF1 receptors (FGFR1)/α‐Klotho complex in the kidney and parathyroid glands.
Giorgia Bertoli, Patrizia Benzoni, Serena Canzolino, David Molla, Raffaella Milanesi, Chiara Piantoni, Makoto Kuro‐o, Carmen Delgado, Gema Ruiz‐Hurtado, Mirko Baruscotti, Annalisa Bucchi   +10 more
wiley   +1 more source

Deciphering key genes in cardio-renal syndrome using network analysis. [PDF]

Bioinformation, 2021
Ahmed MM, Tazyeen S, Alam A, Farooqui A, Ali R, Imam N, Tamkeen N, Ali S, Malik MZ, Ishrat R.   +9 more
europepmc   +1 more source

Cardio renal metabolic syndrome

Abstract Cardio-renal-metabolic syndrome, now commonly referred to as cardiovascular-kidney-metabolic (CKM) syndrome, has emerged as a major clinical concept integrating cardiovascular disease, chronic kidney disease, obesity, diabetes mellitus, and metabolic dysfunction into a single interconnected pathological framework [1].
openaire   +2 more sources

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8836-8846, October 2026.
ABSTRACT Aims To evaluate the effectiveness and safety of tirzepatide on glycaemia, weight, and markers of cardiometabolic risk in people with type 1 diabetes and obesity. Materials and Methods This retrospective cohort study compared 142 adults with type 1 diabetes (BMI ≥ 30 kg/m2) initiated on tirzepatide against 50 age‐, sex‐ and BMI‐matched ...
Simon A. Berry, Iona R. Goodman, Eleanor McNally, Jackie Elliott, Ahmed Iqbal   +4 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE‐RWD)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9461-9472, October 2026.
ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez‐San Miguel, Virginia Soria‐Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez‐Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan J. Gorgojo‐Martínez, Ines Modrego‐Pardo, Irea Fernández‐Xove, Jose Carlos Fernández‐García, Rebeca Reyes‐García   +13 more
wiley   +1 more source

From cardiovascular-kidney-metabolic syndrome to cardio-renal-hepatic-metabolic syndrome: a framework destined to expand further?

Giornale di Clinica Nefrologia e Dialisi
Cardiovascular-kidney-metabolic syndrome (CKM) represents an integrated clinical model describing the interaction among different organs and systems.
Mario D'Agostino, Iole Camilla Iocca, Antonio Nicoletti, Irma Figlia   +3 more
doaj   +1 more source

Distribution of Cardiac and Renal Corin and Proprotein Convertase Subtilisin/Kexin-6 in the Experimental Model of Cardio-Renal Syndrome of Various Severities. [PDF]

Front Physiol, 2021
Khoury EE, Fokra A, Kinaneh S, Knaney Y, Aronson D, Abassi Z.   +5 more
europepmc   +1 more source

Cardio-renal syndromes: a systematic approach for consensus definition and classification

, 2011
The "Cardio-Renal Syndrome" (CRS) is a disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other.
Ronco C, Ronco F, Federico Ronco, Claudio Ronco   +3 more
core   +1 more source